Fig 1.
Immunohistochemical staining of P53 (A), DCR2 (B) and DEC1(C). Ai-Aiv shows clear and distinct nuclear staining of P53 in the respective tissues. Bi-Biv shows DCR2 immunoreactivity in the cytoplasm with minor protein expression masking over the nucleus in the respective tissues. Ci-Civ shows DEC1 moderate and strong granular staining of the cytoplasm in the respective tissues. i: Normal tissue, ii: Atypical Ductal Hyperplasia (ADH), iii: Ductal Carcinoma in situ (DCIS), iv: Invasive ductal carcinoma (IDC). Magnification x400.
Table 1.
Association of protein expression with breast cancer progression.
Table 2.
Association of senescence-associated markers with clinicopathological variables.
Fig 2.
Survival probability based on P53 marker.
A: Disease free survival probability (Kaplan-Meier curve, negative vs. positive, p = 0.002) B: Disease-free survival for hormone therapy (P = 0.005).C: Disease-free survival for chemotherapy (p<0.0001).
Table 3.
Univariate and multivariate cox regression to estimate the hazards ratio.
Fig 3.
Survival probability based on joint effect of P14 and P53 expression.
A: Overall survival, no significant difference was seen between each combination B: Disease free survival probability based on joint effect of P14 and P53 expression. P14+/P53+ VS. P14-/P53- (p = 0.001) and P14+/P53+ vs. P14+/P53- (p = 0.007) showed significant differences in DFS. The worst outcome was seen in patients with P14+/P53+ tumours.
Table 4.
Association of p14 and P53 status with overall and disease-free survival.
Fig 4.
Survival probability based on joint effect of P53 and p16 expression.
A: Overall survival probability, P53+/P16+ VS. P53-/P16- (p = 0.000), P53+/P16+ vs. P53+/P16- (p = 0.008), P53+/P16- VS. P53-/P16+ (p = 0.049) and P53-/P16+ vs. P53-/P16- (p = 0.000) showed significant differences on overall survival. The worst outcome was seen in patients P53+/P16+ tumours.B: Disease free survival, P53+/P16+ VS. P53-/P16- (p = 0.000), P53+/P16+ vs. P53+/P16- (p = 0.017) and P53-/P16+ vs. P53-/P16- (p = 0.000) showed significant differences in DFS. The worst outcome was seen in patients with P53+/P16+ tumours.
Table 5.
Association of P53 and p16 status with overall and disease-free survival.